A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, ...

The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

A new non-opioid painkiller, suzetrigine , has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency ...

Benzamil (the benzyl derivative of the epithelial sodium channel blocker amiloride, a commonly used diuretic agent) showed a marked anticorrelation with psoriasis, which implicated down-regulation ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...